Normal and Pathological Erectile Function The Potential Clinical Role of Endothelin-1 Antagonists

Author(s): M. A. Khan, R. C. Calvert, M. E. Sullivan, C. S. Thomson, F. H. Mumtaz, R. J. Morgan, D. P. Mikhailidis

Journal Name: Current Drug Targets

Volume 1 , Issue 3 , 2000

Become EABM
Become Reviewer

Abstract:

Erectile dysfunction (ED) is a common problem, particularly in older men. The production of penile erection involves an interplay between autonomic nerves and locally released vasoactive mediators. Endothelin-1 (ET-1) is a peptide released from endothelium in the corpus cavernosum, which causes smooth muscle contraction. Recent studies have investigated the physiological significance of ET-1 in the control of erectile function and it may play a role in detumescence. There is also much evidence to link ET-1 to risk factors for ED. ET-1 antagonists may prove beneficial in the treatment of ED and also in prevention of long term deterioration of erectile function. These antagonists may also find a role when used in combination with agents, which are established for the treatment of ED.

Keywords: Endothelin Antagonists, Erectile Dysfunction ED, NO Synthase NOS, Vasoactive Mediators, Ischaemic heart disease, Vasoactive intestinal polypeptide

Rights & PermissionsPrintExport Cite as

Article Details

VOLUME: 1
ISSUE: 3
Year: 2000
Page: [247 - 260]
Pages: 14
DOI: 10.2174/1389450003349164
Price: $65

Article Metrics

PDF: 3